Advocacy Alert

Urge Your Lawmakers to Support Essential Health System Designation

COVID-19: Joint Flu Vaccine Data, Targeted JN.1 Vaccine 

Andrea Lugo
June 11, 2024

Moderna announced June 10 that its phase 3 trial of mRNA-1083, an investigational combination vaccine against influenza and SARS-CoV-2, the virus that causes COVID-19, elicited a higher immune response among adults 50 years old and older compared with standalone vaccines.

Moderna is the first vaccine manufacturer to release positive phase 3 flu and COVID combination vaccine results.

The company plans to present the data findings at an upcoming medical conference and engage with regulators on next steps.

FDA Advisory Committee Votes in Favor of Vaccine Targeting JN.1

Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted June 5 in favor of offering a monovalent vaccine targeting the JN.1 omicron subvariant of the virus in the fall and winter of 2024–2025.

Should the agency approve, this would mean all vaccine manufacturers can target the same subvariant.

JN.1 was the dominant strain at the end of 23, but, as of June 8, KP.3 AND KP.2 make up nearly half of all cases in the United States. Nonetheless, advisors recommended targeting the JN.1 strain instead of more recently emerging strains.

Visit the America’s Essential Hospitals coronavirus resource page for more information about the pandemic.

Contact Director of Policy Rob Nelb, MPH, at rnelb@essentialhospitals.org or 202.585.0127 with questions.

Keep up with the pulse of America's Essential Hospitals

Members: Sign up for email updates.